Google
Trusted Resources: News & Events
Latest announcements and gatherings
Gamida Cell Announces $3.5 Million Grant from the Israeli Government
Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that it has been awarded a grant of $3.5 million from the Israel Innovation Authority (IIA) of the Israeli Ministry of Economy and Industry. The mission of the IIA is to encourage innovation and entrepreneurship in various industries, including science and technology, while stimulating economic growth.
The non-dilutive funding, combined with the $40 million financing round, will support Gamida Cell’s ongoing research and development efforts, including its Phase 3 registration study of NiCord for hematological malignancies, such as leukemia and lymphoma, its clinical trials of CordIn for sickle cell disease and thalassemia, and its NK cell therapy for blood and solid cancers.
+myBinderRelated Content
-
Effects of Hydroxyurea Treatment for Patients With Hemoglobin SC DiseaseAlthough hemoglobin SC (HbSC) disease is...
-
Comparing Sickle Cell Disease Acute Pain Management in the Pediatric and Adult Emergency DepartmentBackground: Vasoocclusive pain leading ...
-
Methadone provides pain relief for kids with sickle cellMany children with sickle cell disease e...
-
Sickle cell patients in UK survey, especially those 16 to 20, voice problems with care and pain relief givenIn a survey, patients across the...
-
Miai & Ama Talk About Sickle Cell Diseasehttps://www.youtube.com/watch?v=7bUFGux-...
-
GBT announces positive top-line data from part A of the phase 3 HOPE study of Voxelotor in sickle cell diseaseGlobal Blood Therapeutics, Inc. today an...
-
Safety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.